Bharat Biotech's oral cholera vaccine Hillchol has demonstrated non-inferiority against both Ogawa and Inaba serotypes in Phase III clinical trials involving 1,800 participants across India.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.